Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
Table of Contents
|2 Review: Evaluating and Regulating Biomarker Use||33-96|
|3 The Biomarker Evaluation Process||97-130|
|4 Case Studies||131-196|
|5 Strengthening Evidence-Based Regulation||197-234|
|Appendix A: Table of Papers About Biomarker Qualification||253-278|
|Appendix B: Recommendations from Related IOM Reports||279-286|
|Appendix C: Committee Member and Consultant Biographies||287-298|
|Appendix D: Staff Biographies||299-304|
|Appendix E: Workshop Agenda||305-306|
|Appendix F: Speaker Biographies||307-314|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease...